APS
MCID: ANT006
MIFTS: 55

Antiphospholipid Syndrome (APS)

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Antiphospholipid Syndrome

MalaCards integrated aliases for Antiphospholipid Syndrome:

Name: Antiphospholipid Syndrome 11 19 42 52 58 75 53 43 14 16 71 33
Antiphospholipid Antibody Syndrome 11 19 42 58 63
Hughes Syndrome 19 42 58 33
Familial Antiphospholipid Syndrome 19 28 71
Acromegaloid Facial Appearance Syndrome 71
Classic Antiphospholipid Syndrome 58
Lupus Anticoagulant, Familial 19
Anti-Phospholipid Syndrome 42
Anticardiolipin Syndrome 33
Classic Apls 58
Apls 58
Aps 19

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases
Rare systemic and rhumatological diseases
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:2988
MeSH 43 D016736
NCIt 49 C61283
SNOMED-CT 68 201450008
Orphanet 58 ORPHA80
UMLS 71 C0085278 C0796280 C2930802

Summaries for Antiphospholipid Syndrome

MedlinePlus Genetics: 42 Antiphospholipid syndrome is a disorder characterized by an increased tendency to form abnormal blood clots (thromboses) that can block blood vessels. This clotting tendency is known as thrombophilia. In antiphospholipid syndrome, the thromboses can develop in nearly any blood vessel in the body. If a blood clot forms in the vessels in the brain, blood flow is impaired and can lead to stroke. Antiphospholipid syndrome is an autoimmune disorder. Autoimmune disorders occur when the immune system attacks the body's own tissues and organs.Women with antiphospholipid syndrome are at increased risk of complications during pregnancy. These complications include pregnancy-induced high blood pressure (preeclampsia), an underdeveloped placenta (placental insufficiency), early delivery, or pregnancy loss (miscarriage). In addition, women with antiphospholipid syndrome are at greater risk of having a thrombosis during pregnancy than at other times during their lives. At birth, infants of mothers with antiphospholipid syndrome may be small and underweight.A thrombosis or pregnancy complication is typically the first sign of antiphospholipid syndrome. This condition usually appears in early to mid-adulthood but can begin at any age.Other signs and symptoms of antiphospholipid syndrome that affect blood cells and vessels include a reduced amount of cells involved in blood clotting called platelets (thrombocytopenia), a shortage of red blood cells (anemia) due to their premature breakdown (hemolysis), and a purplish skin discoloration (livedo reticularis) caused by abnormalities in the tiny blood vessels of the skin. In addition, affected individuals may have open sores (ulcers) on the skin, migraine headaches, or heart disease. Many people with antiphospholipid syndrome also have other autoimmune disorders such as systemic lupus erythematosus.Rarely, people with antiphospholipid syndrome develop thromboses in multiple blood vessels throughout their body. These thromboses block blood flow in affected organs, which impairs their function and ultimately causes organ failure. These individuals are said to have catastrophic antiphospholipid syndrome (CAPS). CAPS typically affects the kidneys, lungs, brain, heart, and liver, and is fatal in over half of affected individuals. Less than 1 percent of individuals with antiphospholipid syndrome develop CAPS.

MalaCards based summary: Antiphospholipid Syndrome, also known as antiphospholipid antibody syndrome, is related to libman-sacks endocarditis and pregnancy loss, recurrent 1, and has symptoms including unspecified visual loss An important gene associated with Antiphospholipid Syndrome is APOH (Apolipoprotein H), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Warfarin and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include placenta, heart and brain, and related phenotypes are homeostasis/metabolism and cardiovascular system

NINDS: 52 Antiphospholipid syndrome (APS) is an autoimmune disorder caused when antibodies -- immune system cells that fight off bacteria and viruses -- mistakenly attack healthy body tissues and organs.  In APS, specific antibodies activate the inner lining of blood vessels, which leads to the formation of blood clots in arteries or veins.  APS is sometimes called “sticky blood syndrome,” because of the increased tendency to form blood clots in the veins and arteries.  The symptoms of APS are due to the abnormal blood clotting.  Clots can develop in the veins of the legs and lungs, or in the placenta of pregnant women.  One of the most serious complications of APS occurs when a clot forms in the brain and causes a stroke.  Other neurological symptoms include chronic headaches, dementia (similar to the dementia of Alzheimer’s disease), and seizures.  Infrequently, individuals will develop chorea (a movement disorder in which the body and limbs writhe uncontrollably), cognitive dysfunction (such as poor memory), transverse myelitis, depression or psychosis, optic neuropathy, or sudden hearing loss.  In pregnant women, clots in the placenta can cause miscarriages.  APS is diagnosed by the presence of a positive antiphospholipid antibody and either a history of blood clots in an artery or vein or a history of multiple miscarriages or other pregnancy problems.  Some individuals will have a characteristic lacy, net-like red rash called livedo reticularis over their wrists and knees.

PubMed Health : 63 Antiphospholipid antibody syndrome: Antiphospholipid (AN-te-fos-fo-LIP-id) antibody syndrome (APS) is an autoimmune disorder. Autoimmune disorders occur if the body's immune system makes antibodies that attack and damage tissues or cells. Antibodies are a type of protein. They usually help defend the body against infections. In APS, however, the body makes antibodies that mistakenly attack phospholipids—a type of fat. Phospholipids are found in all living cells and cell membranes, including blood cells and the lining of blood vessels. When antibodies attack phospholipids, cells are damaged. This damage causes blood clots to form in the body's arteries and veins. (These are the vessels that carry blood to your heart and body.) Usually, blood clotting is a normal bodily process. Blood clots help seal small cuts or breaks on blood vessel walls. This prevents you from losing too much blood. In APS, however, too much blood clotting can block blood flow and damage the body's organs.

GARD: 19 Antiphospholipid syndrome (APS) is an autoimmune disorder. Signs and symptoms vary, but may include blood clots, miscarriage, rash, chronic headaches, dementia, and seizures. APS occurs when your body's immune system makes antibodies that attack phospholipids. Phospholipids are a type of fat found in all living cells, including blood cells and the lining of blood vessels. Most cases of APS occur in people with no family history of the disorder, however there are rare cases of APS clustering in a family. A widely accepted explanation for APS is that it is caused by a combination of genetic changes (making one more susceptible to APS) and an environmental exposure (such as to a virus).

Disease Ontology: 11 An autoimmune disease that is characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with characteristic elevated levels of antibodies directed against membrane anionic phospholipids (anticardiolipin).

Wikipedia: 75 Antiphospholipid syndrome, or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune,... more...

Related Diseases for Antiphospholipid Syndrome

Diseases in the Antiphospholipid Syndrome family:

Antiphospholipid Syndrome, Familial

Diseases related to Antiphospholipid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1150)
# Related Disease Score Top Affiliating Genes
1 libman-sacks endocarditis 32.3 F2 APOH
2 pregnancy loss, recurrent 1 31.8 MTHFR F5 APOH
3 vitamin k deficiency bleeding 31.7 SERPINC1 F3 F2
4 heparin-induced thrombocytopenia 31.3 F3 F2
5 heart valve disease 31.3 VWF F3 F2 APOH
6 eclampsia 31.2 THBD SERPINC1 MTHFR F3 F2 APOH
7 anemia, autoimmune hemolytic 31.2 CD40LG APOH ADAMTS13
8 placental insufficiency 31.2 SERPINC1 SELP F3 F2
9 infective endocarditis 31.2 VWF F3 F2
10 thrombocytopenia due to platelet alloimmunization 31.1 VWF SELP F3 ADAMTS13
11 amaurosis fugax 31.1 MTHFR F5
12 sneddon syndrome 31.1 SERPINC1 F5 F2 APOH
13 hemolytic anemia 31.0 VWF THBD F3 CFH APOH ADAMTS13
14 thrombocytopenic purpura, autoimmune 31.0 SELP F3 F2 ADAMTS13
15 acute kidney failure 31.0 F2 CFH ADAMTS13
16 thrombophilia due to thrombin defect 31.0 VWF THBD SERPINC1 SELP PROCR PLAT
17 migraine with or without aura 1 31.0 VWF MTHFR F3 F2 APOH
18 splenic infarction 31.0 SERPINC1 F3 F2 APOH
19 endocarditis 31.0 VCAM1 SERPINC1 PLAT F2 APOH
20 thrombotic thrombocytopenic purpura, hereditary 30.9 CFH ADAMTS13
21 hepatic infarction 30.9 SERPINC1 F3 F2 APOH
22 purpura 30.9 VWF THBD SERPINC1 SELP F3 F2
23 osteonecrosis 30.8 SERPINC1 MTHFR F2 ANXA5 ANXA2
24 transient cerebral ischemia 30.8 VWF SERPINC1 PLAT MTHFR F3 F2
25 limb ischemia 30.8 VWF SERPINC1 F3
26 coronary thrombosis 30.8 VWF SERPINC1 PLAT F3
27 placental abruption 30.8 SERPINC1 MTHFR F5 F3 F2 APOH
28 respiratory failure 30.8 VWF THBD SERPINC1 F3 F2
29 tricuspid valve insufficiency 30.8 PLAT F3 F2
30 retinal artery occlusion 30.8 SERPINC1 MTHFR F5 F2 APOH
31 budd-chiari syndrome 30.8 VWF SERPINC1 MTHFR F5 F3 F2
32 aortic valve insufficiency 30.8 VWF PON1 F3 F2
33 adult respiratory distress syndrome 30.7 THBD SELP SELE F5
34 pulmonary embolism 30.7 VWF THBD SERPINC1 PLAT MTHFR F5
35 mixed connective tissue disease 30.7 CD40LG APOH ADAMTS13
36 nonbacterial thrombotic endocarditis 30.7 VWF SERPINC1 PLAT F3 F2 APOH
37 cardiac tamponade 30.7 PLAT F3 F2
38 nonarteritic anterior ischemic optic neuropathy 30.7 SERPINC1 MTHFR F5 F2
39 hemophilia 30.7 VWF F2 F10
40 cerebrovascular disease 30.7 SELP PON1 PLAT MTHFR F5 F2
41 cerebral sinovenous thrombosis 30.7 F5 F2
42 ischemic colitis 30.7 SERPINC1 F3 F2
43 collagen disease 30.7 VWF THBD APOH
44 livedoid vasculitis 30.6 SERPINC1 MTHFR F3 F2 APOH
45 acalculous cholecystitis 30.6 F3 F2
46 retinal vein occlusion 30.6 VWF SERPINC1 MTHFR F5 F3 F2
47 deficiency anemia 30.6 VWF SERPINC1 PON1 F3 F2 CFH
48 malignant hypertension 30.6 VWF CFH ADAMTS13
49 toxoplasmosis 30.6 F2 CD40LG ANXA5
50 blue toe syndrome 30.6 F3 F2

Graphical network of the top 20 diseases related to Antiphospholipid Syndrome:



Diseases related to Antiphospholipid Syndrome

Symptoms & Phenotypes for Antiphospholipid Syndrome

UMLS symptoms related to Antiphospholipid Syndrome:


unspecified visual loss

GenomeRNAi Phenotypes related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.23 ADAMTS13 ANXA2 ANXA5 APOH CD40LG CFH
2 no effect GR00402-S-2 10.23 ADAMTS13 ANXA2 ANXA5 APOH CD40LG CFH

MGI Mouse Phenotypes related to Antiphospholipid Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 ADAMTS13 ANXA2 APOH CD40LG CFH F10
2 cardiovascular system MP:0005385 10.22 ANXA2 CD40LG CFH F10 F2 F3
3 growth/size/body region MP:0005378 10.21 ANXA2 CFH F10 F2 F3 F5
4 nervous system MP:0003631 10.17 CD40LG CFH F2 F3 F5 MTHFR
5 immune system MP:0005387 10.1 ADAMTS13 ANXA5 CD40LG CFH F2 F3
6 hematopoietic system MP:0005397 10.03 ADAMTS13 ANXA2 ANXA5 CD40LG CFH F2
7 mortality/aging MP:0010768 9.89 ADAMTS13 APOH CD40LG CFH F10 F2
8 integument MP:0010771 9.28 CD40LG F2 F3 F5 MTHFR PLAT

Drugs & Therapeutics for Antiphospholipid Syndrome

PubMed Health treatment related to Antiphospholipid Syndrome: 63

Antiphospholipid antibody syndrome (APS) has no cure. However, medicines can help prevent complications. The goals of treatment are to prevent blood clots from forming and keep existing clots from getting larger. You may have APS and another autoimmune disorder , such as lupus . If so, it's important to control that condition as well. When the other condition is controlled, APS may cause fewer problems. Research is ongoing for new ways to treat APS.

Drugs for Antiphospholipid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2, 129-06-6 54678486
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Apixaban Approved Phase 4 503612-47-3 10182969
4 Vaccines Phase 4
5
Acenocoumarol Approved, Investigational Phase 3 152-72-7 54676537 9052
6
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
7
Tannic acid Approved Phase 2, Phase 3 1401-55-4 16129878 16129778
8
Belimumab Approved Phase 2, Phase 3 356547-88-1
9
Rivaroxaban Approved Phase 3 366789-02-8 9875401
10
Hydroxychloroquine Approved Phase 3 118-42-3 3652
11 Antivitamins K Phase 3
12 Immunologic Factors Phase 2, Phase 3
13 Immunosuppressive Agents Phase 2, Phase 3
14 Factor Xa Inhibitors Phase 3
15 HIV Protease Inhibitors Phase 3
16 Serine Proteinase Inhibitors Phase 3
17 Antithrombins Phase 3
18 Antithrombin III Phase 3
19
protease inhibitors Phase 3
20 Antirheumatic Agents Phase 3
21 Anti-Infective Agents Phase 3
22 Antiprotozoal Agents Phase 3
23 Antiparasitic Agents Phase 3
24 Antimalarials Phase 3
25 Autoantibodies Phase 3
26
Serine Investigational, Nutraceutical Phase 3 56-45-1 5951
27
Rituximab Approved Phase 2 174722-31-7
28
Eculizumab Approved, Investigational Phase 2 219685-50-4
29
Zanubrutinib Approved, Investigational Phase 2 1691249-45-2 135565884
30
Certolizumab pegol Approved Phase 2 428863-50-7
31 Antineoplastic Agents, Immunological Phase 2
32 Hormones Phase 2
33 Calcium, Dietary Phase 2
34 Complement System Proteins Phase 2
35 Protein Kinase Inhibitors Phase 2
36
Calcium Nutraceutical Phase 2 7440-70-2 271
37
Lenograstim Approved, Investigational 135968-09-1
38
Rofecoxib Approved, Investigational, Withdrawn 162011-90-7 5090
39
Celecoxib Approved, Investigational 169590-42-5 2662
40
Phylloquinone Approved, Investigational 84-80-0 5284607
41
Sodium citrate Approved, Investigational 68-04-2 23431961
42
Edoxaban Approved 480449-70-5 11635624 10280735
43
Dabigatran Approved, Investigational 211914-51-1 216210
44
Plasminogen Approved 9001-91-6
45
Thrombin Approved, Investigational
46
Protein C Approved
47
Lysine Approved, Nutraceutical 56-87-1 5962
48
Menadione Approved, Nutraceutical 58-27-5 4055
49
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
50 Menaquinone Investigational 1182-68-9

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome Unknown status NCT02303171 Phase 4 Enoxaparin;Warfarin
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Rivaroxaban in Antiphospholipid Syndrome Pilot Study: A Multicenter Feasibility Study of Rivaroxaban for Patients With Antiphospholipid Syndrome and Prior Arterial or Venous Thrombosis Completed NCT02116036 Phase 4 Rivaroxaban
4 Timing of Initiation of Low Molecular Weight Heparin Administration in Pregnant Women With Antiphospholipid Syndrome Completed NCT02326051 Phase 4 Enoxaparin
5 Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial Completed NCT01104337 Phase 4 paracetamol;Placebo
6 Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome Active, not recruiting NCT02295475 Phase 4 Apixaban;Warfarin
7 A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome Not yet recruiting NCT04624269 Phase 4 Hydroxychloroquine Sulfate Tablets
8 Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome? Withdrawn NCT04274803 Phase 4 Intralipid, 20% Intravenous Emulsion;Conventional therapy of antiphospholipis syndrome
9 Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome Unknown status NCT03540810 Phase 3 Hydroxychloroquine;Placebo
10 Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors Completed NCT02926170 Phase 3 Rivaroxaban;acenocumarol
11 Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open Label, Phase II/III, Non-inferiority Trial Recruiting NCT03684564 Phase 2, Phase 3 Rivaroxaban;Warfarin
12 Open-label, Prospective, Phase II Descriptive Pilot Trial of Belimumab Therapy for Refractory and/or Non-criteria Manifestations of Antiphospholipid Syndrome Recruiting NCT05020782 Phase 2, Phase 3 Belimumab
13 A Prospective, Randomized Clinical Trial Comparing Rivaroxaban vs Warfarin in High Risk Patients With Antiphospholipid Syndrome Terminated NCT02157272 Phase 3 Experimental: Rivaroxaban
14 A Prospective Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of aPL Positive But Thrombosis-free Patients. Terminated NCT01784523 Phase 3 Hydroxychloroquine
15 Efficiency of Hydroxychloroquine on the Endothelial Dysfunction in Antiphospholipid Syndrome (APLAQUINE) Unknown status NCT02595346 Phase 2 Hydroxychloroquine;placebo
16 Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS Unknown status NCT00180778 Phase 1, Phase 2 Low dose steroids
17 A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome (RITAPS) Completed NCT00537290 Phase 2 Rituximab
18 Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients Completed NCT00674297 Phase 2 Fluvastatin
19 Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial Completed NCT01051778 Phase 2 enoxaparin 40mg plus low dose aspirin;Heparin calcium5,000 U twice daily plus low dose aspirin
20 Eculizumab to Enable Renal Transplantation in Patients With History of Antiphospholipid Antibody Syndrome or Catastrophic Antiphospholipid Antibody Syndrome Completed NCT01029587 Phase 2 Eculizumab
21 Evaluation of the Benefit of Adjuvant Treatment With Hydroxychloroquine to the Usual Medical Management for Obtaining an Uncomplicated Term Pregnancy in Primary Obstetric Antiphospholipid Syndrome Recruiting NCT04275778 Phase 2 Plaquenil 200Mg Tablet;Placebo oral tablet
22 Prospective, Single Arm and Open Clinical Observation of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia Recruiting NCT05199909 Phase 2 zanubrutinib
23 Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy) Recruiting NCT03152058 Phase 2 Certolizumab Pegol
24 A Pilot Study of Telitacicept Treatment in Primary APS Patients Recruiting NCT05078710 Phase 2 Telitacicept
25 An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome Terminated NCT02128269 Phase 2
26 High Dose Cyclophosphamide & CAMPATH-1H With Hematopoietic Stem Cell Transplantation in Patients With Refractory Antiphospholipid Syndrome (APS): A Phase I Trial Withdrawn NCT00278616 Phase 1
27 Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome Unknown status NCT01956188
28 A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS) Unknown status NCT01661439 low molecular weight heparin (enoxeparine)
29 TheValue of Placental Vascularization Indices and Placental Volume in Pregnancies With Antiphospholipid Syndrome for Prediction of Neonatal Outcome" Unknown status NCT03505840
30 Detection Of Anti-Double Stranded Deoxyribonucleic Acid Antibodies In Autoimmune Rheumatic Diseases: Comparison Between Immunofluorescence And Enzyme Immunoassay Unknown status NCT03303508
31 Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX) Unknown status NCT03994302 Drug inducing antiphospholipid syndrome
32 Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients Unknown status NCT03384485
33 The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome Unknown status NCT01818505
34 Antiphospholipid Antibodies and Early Fetal Growth Restriction (<34 Weeks of Gestation). A Case Control Study. Unknown status NCT01538134
35 Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study. Unknown status NCT01538121
36 Assessement of a Multi-organ Screening Procedure for the Detection of Pre-clinical Ischaemia in Antiphospholipid Syndrome The COBRA Study (CardiO-Brain Renal Involvement in Antiphospholipid Syndrome) Completed NCT03348306
37 Effect of Hydroxychloroquine on Thrombosis Prevention and Antiphospholipid Antibody Levels in Patients With Primary Antiphospholipid Syndrome: An Pilot Randomized Prospective Study. Completed NCT04153201 Hydroxychloroquine
38 Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White Matter Completed NCT03600636
39 Monitoring Anticoagulant Therapy With Vitamin-K Antagonists in Patients With Antiphospholipid Syndrome Completed NCT01660061
40 Antiphospholipid Syndrome Collaborative Registry (APSCORE) Completed NCT00076713
41 Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System): Marker of Venous Thrombosis Risk in Systemic Lupus and Antiphospholipid Syndrome? Case-control Study Completed NCT02892565
42 Ocular Findings in Women With Primary Antiphospholipid Syndrome and Their Association to Bad Obstetric Outcome Completed NCT03459508
43 Clinical Features and Pattern of Antiphospholipid Antibodies in Patients of Antiphospholipid Syndrome (APS) With Systemic Lupus Erythematosus (SLE). Completed NCT04963881
44 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
45 Evaluation of the Precision and Accuracy of International Normalised Ratio (INR) Measurements as Assessed by the LumiraDx Instrument in a Professional Point of Care Setting With Multiple Operators Completed NCT03682419
46 Retrospective Study of the Prevalence of Antiphospholipid Antibodies in the Population of Hemodialysis Patients at the CHU Brugmann Hospital Completed NCT03893357
47 Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies in Women Presenting as Recurrent Miscarriages. Completed NCT00180817
48 INR Determined by Plasma-based Methods Versus Newer Point-of-care Instruments in Patients With Antiphospholipid-antibody Syndrome Treated With Anticoagulants Completed NCT00878137
49 Evaluation of the Incidence of Cancer in the Follow-up of Women With 3 Consecutive Embryonic Demises Before 10 Weeks or 1 Fetal Death, According to Their Thrombophilia Status, With a Special Focus on Women With an Obstetric Antiphospholipid Symdrome (oAPS) Completed NCT03969498
50 Effect of Hydroxychloroquine on the Annexin A5 Resistance Assay in Antiphospholipid Antibody-Positive Patients With and Without Systemic Lupus Erythematosus Completed NCT01475149

Search NIH Clinical Center for Antiphospholipid Syndrome

Cochrane evidence based reviews: antiphospholipid syndrome

Genetic Tests for Antiphospholipid Syndrome

Genetic tests related to Antiphospholipid Syndrome:

# Genetic test Affiliating Genes
1 Familial Antiphospholipid Syndrome 28

Anatomical Context for Antiphospholipid Syndrome

Organs/tissues related to Antiphospholipid Syndrome:

MalaCards : Placenta, Heart, Brain, Skin, Liver, Bone, Endothelial

Publications for Antiphospholipid Syndrome

Articles related to Antiphospholipid Syndrome:

(show top 50) (show all 10869)
# Title Authors PMID Year
1
Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. 53 62
20483743 2010
2
Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? 53 62
20353991 2010
3
Mode of interaction between beta2GPI and lipoprotein receptors suggests mutually exclusive binding of beta2GPI to the receptors and anionic phospholipids. 53 62
20223219 2010
4
Etanercept and venous thromboembolism: a case series. 53 62
20157435 2010
5
Thyroid-associated autoimmune coagulation disorders. 53 62
19277469 2010
6
{beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. 53 62
19805618 2010
7
Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity. 53 62
19920091 2010
8
Structural insights into recognition of beta2-glycoprotein I by the lipoprotein receptors. 53 62
19676115 2009
9
Autoantibodies against phosphatidylserine, prothrombin and phosphatidylserine-prothrombin complex: identical or distinct diagnostic tools for antiphospholipid syndrome? 53 62
19751711 2009
10
Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. 53 62
19556010 2009
11
Venous thromboembolism in young female while on oral contraceptives: high frequency of inherited thrombophilia and analysis of thrombotic events in 400 czech women. 53 62
19117968 2009
12
Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. 53 62
19811220 2009
13
[Cerebral venous thrombosis: when etiology makes the difference]. 53 62
19921552 2009
14
Prevalence of anticardiolipin antibodies in patient cohorts with distinct clinical manifestations of the antiphospholipid syndrome. 53 62
19758143 2009
15
Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. 53 62
19755700 2009
16
Beta2-glycoprotein I and annexin A5 phospholipid interactions: artificial and cell membranes. 53 62
19232551 2009
17
Factor V Leiden mutation and antiphospholipid syndrome: risk factors for atherosclerotic and arterial thromboembolic disease. 53 62
19574060 2009
18
The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. 53 62
19644870 2009
19
[Hypercoagulable workup in ophthalmology. When and what]. 53 62
19658050 2009
20
Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. 53 62
19101711 2009
21
Thrombophilia: 2009 update. 53 62
19289024 2009
22
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. 53 62
19155517 2009
23
Is there an overlap between sudden neurosensorial hearing loss and cardiovascular risk factors? 53 62
19005247 2009
24
Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss. 53 62
18826497 2008
25
[Pre-eclampsia screening in first and second trimester]. 53 62
18979429 2008
26
Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. 53 62
18827057 2008
27
Tissue factor in the antiphospholipid syndrome. 53 62
18827061 2008
28
Annexin A2: biology and relevance to the antiphospholipid syndrome. 53 62
18827060 2008
29
Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndrome. 53 62
17828468 2008
30
The antiphospholipid syndrome. 53 62
19028366 2008
31
Antibodies to anionic phospholipids and cofactors in kala-azar. Comparative study with malaria, toxoplasmosis and "autoimmune diseases". 53 62
19032825 2008
32
[Sagittal sinus thrombosis as a rare cause of postpartum headache: a case report]. 53 62
18853684 2008
33
The activated seven lupus anticoagulant assay detects clinically significant antibodies. 53 62
17895508 2008
34
Placental fas/fas ligand expression in early pregnancy losses. 53 62
18422813 2008
35
Venous thromboembolism during pregnancy. 53 62
18619081 2008
36
Etiological profile of stroke and its relation with prothrombotic states. 53 62
18759085 2008
37
The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. 53 62
18341632 2008
38
Recurrent ischemic colitis in a patient with leiden factor V mutation and systemic lupus erythematous with antiphospholipid syndrome. 53 62
18504175 2008
39
Jejunal ischaemia-- rare aetiologies and a surgical dilemma. 53 62
18720940 2008
40
Eighteen years of liver transplantation experience in patients with advanced Budd-Chiari syndrome. 53 62
18236386 2008
41
[Diagnosis of secondary antiphospholipid syndrome in children by means of screening tests]. 53 62
18354917 2008
42
Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins. 53 62
18180621 2008
43
Acquired angioedema associated with primary antiphospholipid syndrome in a patient with antithrombin III deficiency. 53 62
18204284 2008
44
Multifactorial thrombophilia in a pregnancy: a case report. 53 62
17895510 2008
45
Thrombophilia and cerebral vein thrombosis. 53 62
18004053 2008
46
Atherothrombosis: environmental links. 53 62
19024794 2008
47
Sole existence of antithrombin antibody in patients with systemic lupus erythematosus showing tendency of its antigenic determinants directing against exosite II (antithrombin/heparin binding site) of thrombin. 53 62
18180618 2008
48
Traditional and nontraditional risk factors for atherosclerosis in patients with systemic lupus erythematosus. 53 62
19366077 2008
49
Specificity and sensitivity of anti-beta2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome. 53 62
17332980 2007
50
[Treatment of antiphospholipid syndrome]. 53 62
18303659 2007

Variations for Antiphospholipid Syndrome

Copy number variations for Antiphospholipid Syndrome from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 160790 22 16300000 24300000 Deletion Hughes'' syndrome

Expression for Antiphospholipid Syndrome

Search GEO for disease gene expression data for Antiphospholipid Syndrome.

Pathways for Antiphospholipid Syndrome

Pathways related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.53 VWF THBD SERPINC1 SELP SELE PROCR
2
Show member pathways
12.5 THBD SERPINC1 F5 F3 F2 F10
3
Show member pathways
12.32 SELP SELE F2 F10 CFH
4
Show member pathways
12.11 VWF THBD SERPINC1 PROCR PLAT F5
5
Show member pathways
11.89 THBD SELP SELE PROCR F2
6
Show member pathways
11.38 VCAM1 SELE CD40LG
7 10.92 CD40LG F10 PLAT VCAM1
8 10.55 PLAT ANXA2

GO Terms for Antiphospholipid Syndrome

Cellular components related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005887 10.48 CD40LG F3 PROCR SELE SELP THBD
2 plasma membrane GO:0005886 10.48 CD40LG F3 PROCR SELE SELP THBD
3 extracellular exosome GO:0070062 10.47 ANXA2 ANXA5 APOH CFH F2 PLAT
4 cell surface GO:0009986 10.32 VCAM1 THBD PROCR PLAT F3 CD40LG
5 extracellular region GO:0005576 10.29 ADAMTS13 ANXA2 ANXA5 APOH CD40LG CFH
6 collagen-containing extracellular matrix GO:0062023 10.2 ANXA2 ANXA5 APOH F2 F3 PLAT
7 endoplasmic reticulum lumen GO:0005788 10.19 SERPINC1 F5 F2 F10 ADAMTS13
8 blood microparticle GO:0072562 10.08 SERPINC1 PON1 F2 CFH
9 extracellular space GO:0005615 9.88 ADAMTS13 ANXA2 APOH CD40LG CFH F10
10 serine-type endopeptidase complex GO:1905370 9.86 THBD F2 F10 CFH
11 external side of plasma membrane GO:0009897 9.86 ANXA5 CD40LG F10 F2 F3 SELE
12 obsolete intrinsic component of external side of plasma membrane GO:0031233 9.4 F3 F10

Biological processes related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 10.29 THBD PLAT F2 F10 CFH ADAMTS13
2 response to lipopolysaccharide GO:0032496 10.1 SELE SELP THBD VCAM1
3 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 10.01 VCAM1 SELP SELE
4 platelet activation GO:0030168 10.01 ADAMTS13 CD40LG F2 VWF
5 blood coagulation GO:0007596 9.98 ADAMTS13 ANXA5 F10 F2 F3 F5
6 leukocyte tethering or rolling GO:0050901 9.93 VCAM1 SELP SELE
7 fibrinolysis GO:0042730 9.91 PLAT F2 ANXA2
8 leukocyte cell-cell adhesion GO:0007159 9.86 VCAM1 SELP SELE CD40LG
9 negative regulation of platelet activation GO:0010544 9.85 THBD F2
10 negative regulation of coagulation GO:0050819 9.78 PROCR ANXA5
11 negative regulation of fibrinolysis GO:0051918 9.76 APOH F2 PLAT THBD
12 positive regulation of binding GO:0051099 9.7 PON1 ANXA2
13 regulation of blood coagulation GO:0030193 9.67 SERPINC1 F2 APOH
14 regulation of body fluid levels GO:0050878 9.5 F5 F2 F10
15 hemostasis GO:0007599 9.36 ADAMTS13 ANXA5 F10 F2 F3 F5

Molecular functions related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.92 VWF VCAM1 CD40LG ADAMTS13
2 protease binding GO:0002020 9.86 VWF SERPINC1 F3 ANXA2
3 calcium ion binding GO:0005509 9.86 THBD SELP PON1 F2 F10 ANXA5
4 heparin binding GO:0008201 9.85 APOH CFH F2 SELP SERPINC1
5 phospholipase inhibitor activity GO:0004859 9.54 ANXA5 ANXA2
6 phospholipid binding GO:0005543 9.32 PON1 F3 F10 APOH ANXA5

Sources for Antiphospholipid Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....